As previously announced, on March 24, 2024, Landos Biopharma, Inc. entered into an Agreement and Plan of Merger with Bespin Subsidiary, LLC, a wholly owned Subsidiary of Guarantor (?Parent?), Bespin Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and solely for the limited purposes therein, AbbVie Inc. (?AbbVie? or ?Guarantor?) providing for, among other things, the merger of Merger Sub with and into the Company (Merger), with the Company surviving the Merger as a wholly owned subsidiary of Parent. On May 23, 2024, the Company completed the Merger.

Pursuant to the Merger Agreement, effective as of, and contingent upon, the occurrence of the closing of the Merger (the ?Closing?), all of the Company?s directors voluntarily resigned from the Company?s board of directors and the directors of Merger Sub immediately prior to the Effective Time became the directors of the Company. In addition, as of the Effective Time, each of the Company?s executive officers no longer serves in their respective positions at the Company.